Advances in malignant hyperthermia: pathophysiology, diagnosis and management

Read full text Summarise with VIRAT
Authors: Shaistha Banu, Sushmitha R Shenoy
Cited by: 0
References: 25

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Malignant hyperthermia (MH) is a rare genetic disorder triggered by volatile anaesthestics and depolarizing muscle relaxants like sevoflurane, desflurane, and succinylcholine. It is mainly associated with pathogenic variants in the RYR1 and CACNA1S genes that disrupt calcium regulation in skeletal muscles, causing uncontrolled calcium release from the sarcoplasmic reticulum and a hypermetabolic crisis with rhabdomyolysis, muscle rigidity, hypercapnia, hyperthermia, and multiorgan failure. Since its first clinical description in the 1960s, clinical signs such as tachycardia, rising end-tidal CO₂ (ETCO₂), and sudden hyperthermia remain essential for detection. Diagnosis relies on invasive muscle contracture tests like the Caffeine-Halothane contracture test (CHCT) and in vitro contracture test (IVCT). Next-generation sequencing (NGS) identifies mutations in RYR1, CACNA1S, and related excitation–contraction coupling genes. Despite incomplete genotype-phenotype correlations, mechanisms including oxidative stress and sodium-calcium channel dysregulation improve understanding of MH susceptibility. Management requires immediate cessation of triggering agents, intravenous dantrolene, and supportive care including cooling, correction of acidosis, electrolyte control, and monitoring of cardiac and renal complications. Patients should be monitored for recurrence within 24 hours and receive genetic counselling, medical alert identification, and family screening due to autosomal dominant inheritance. Emerging research explores CRISPR/Cas9 correction of RYR1 mutations, antisense oligonucleotide therapy to suppress mutant transcripts, and antioxidants N-acetylcysteine and Trolox to reduce reactive oxygen species-mediated muscle injury; animal studies show improved calcium regulation but human trials are needed. Preventive measures include temperature and ETCO₂ monitoring, regional anaesthesia in obstetrics, and total intravenous anaesthesia, when necessary, supported by collaboration among anaesthesiologists, geneticists, intensivists, and surgeons.

Fields of Study & Subjects

Anesthesia and Sedative Agents Ion channel regulation and function Muscle and Compartmental Disorders

Publication details

Journal / source
International Journal of Research in Medical Sciences
Volume
14
Issue
4
Pages
1759–1767
Publication date
30 March 2026
Language
EN